C71T
CANCELLED SECTION 71
06/26/2026
Back to search
Official data from USPTO
OXURION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
07/21/2026
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
12/18/2018
Registration date
12/10/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/26/2026
Last transaction
07/21/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
5
Owner type
32
Owner location
BE
Examiner
HARMON, RAYMOND E
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "OXURION" in stylized text, where the letters "O" and "URION" are in blue and the "X" is in a larger, slanted font in green.
Holders and representatives
Holders
Oxurion
Representatives
Martin W. Schiffmiller Kirschstein Israel Schiffmiller & Pieron
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biopharmaceutical preparations for use in the treatment of hypertensionstrokescardiac diseases and vascular diseases; diagnostic medical reagentschemicals preparations and biological materialsall the foregoing being in the form of spatially defined arrays and solutions and reagents for medical laboratory use in diagnosingmonitoringpredicting diseases and for measuring and predicting response to therapy of cardiac and vascular diseases; pharmaceutical preparations for use in the treatment of hypertensionstrokescardiac diseases and vascular diseases; pharmaceutical substances and medicines for treatment or prevention of eye disorders and diseases and of ophthalmological disorders and diseases; pharmaceutical preparations and substances for the treatment or prevention of diabetes; medicines for treating or preventing diabetes; ophthalmic medicines and surgical fluidsophthalmic pharmaceutical preparations; pharmaceutical eye drops
Class 42
Scientific and technological servicesnamely research and design relating thereto in the field of ophthalmologyin the field of diabetes and in the field of treatment of cardiovascular diseasecardiac disease and vascular disease; industrial analysis of the pharmaceutical preparations of others used for the treatment of ophthalmologic diseasesdiabetes and cardiovascular diseases for quality control purposes; research services in the field of ophthalmologydiabetes and cardiovascular diseases; pharmaceutical and biopharmaceutical research and development; biopharmaceutical product evaluation; research in the field of treatment of cardiovascular diseasecardiac diseasevascular disease; development of new treatments for pathologies in which vascular biology plays a critical role in the field of biopharmaceuticals
Class 44
Medical services; veterinary services; consultancy servicesconsultancy in the medicalveterinary and pharmaceutical treatment of patients in the fields of ophthalmologydiabetes and cardiovascular diseases; medical servicescardiac and vascular therapeuticprognostic and diagnostic testing services
Publications
History of USPTO decisions and trademark events.
34 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/26/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/08/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/10/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/10/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/23/2020
FIMP
FINAL DISPOSITION PROCESSED
03/23/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/10/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
12/10/2019
GPNX
NOTIFICATION PROCESSED BY IB
10/05/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/24/2019
PUBO
PUBLISHED FOR OPPOSITION
09/24/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/18/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/18/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/04/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/16/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
08/16/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/16/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
08/16/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/16/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/23/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/22/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/22/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/22/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/22/2019
RFNT
REFUSAL PROCESSED BY IB
04/12/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/28/2019
RFRR
REFUSAL PROCESSED BY MPU
03/27/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/19/2019
CNRT
NON-FINAL ACTION WRITTEN
03/18/2019
MAFR
APPLICATION FILING RECEIPT MAILED
03/16/2019
DOCK
ASSIGNED TO EXAMINER
03/13/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/12/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/07/2019
Continuous trademark protection
Get notified about every new filing that threatens OXURION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.